Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026
Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026
Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026
Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026
Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026
Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026
Company Legal / IP

Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US

Fineline Cube Sep 5, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical...

Company Drug

Columbia University Study Weighs Cost-Effectiveness of Weight-Loss Treatments for Adolescents

Fineline Cube Sep 5, 2023

Researchers at US Columbia University have published the results of a study estimating the cost-effectiveness...

Company

Shanghai Pharmaceuticals Executives Under Investigation for Serious Disciplinary Violations

Fineline Cube Sep 5, 2023

China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has disclosed that several...

Company Drug

BDgene Technology Announces Clinical Milestone for CRISPR-Cas9 Gene Therapy in HSK

Fineline Cube Sep 5, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced the conclusion of three clinical...

Company

Sanofi Announces Management Restructuring with New Leadership Roles in China

Fineline Cube Sep 5, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced a significant restructuring of its management structure...

Company Deals

ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO

Fineline Cube Sep 5, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock...

Company Drug

Sihuan Pharmaceutical’s Birociclib NDA Accepted for Review by China’s NMPA

Fineline Cube Sep 5, 2023

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that the National Medical Products...

Company Deals

Bloomage Biotech Terminates Joint Venture with Medytox Inc. for Botulinum Toxin Development

Fineline Cube Sep 5, 2023

China-based Bloomage Biotech (SHA: 688363) has revealed that a termination agreement has been signed with...

Company Drug

Jointown Medical’s COVID-19 Drug Candidate SHEN211 Accepted for Review by NMPA

Fineline Cube Sep 5, 2023

China-based Jointown Medical Devices Group Co., Ltd (SHA: 600998) has announced that its clinical trial...

Company Drug

Hansoh Pharmaceutical Receives NMPA Approval for Generic Ofev (Nintedanib)

Fineline Cube Sep 5, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received marketing...

Company Deals

Pilot Gene Technology Secures $13.8 Million in Series B Financing for Diagnostic Expansion

Fineline Cube Sep 4, 2023

China-based diagnostic reagents specialist, Pilot Gene Technology (Hangzhou) Co., Ltd, has reportedly raised RMB 100...

Company Drug

Chia Tai Tianqing’s Generic Entresto Approved by NMPA, Launch Expected in 2026

Fineline Cube Sep 4, 2023

The National Medical Products Administration (NMPA) website has indicated that Chia Tai Tianqing’s generic version...

Company Drug

Novo Nordisk’s Esperoct on Track for Priority Review in Hemophilia A Treatment

Fineline Cube Sep 4, 2023

The Center for Drug Evaluation (CDE) website has indicated that Denmark-based Novo Nordisk’s (NYSE: NVO)...

Company Drug

Bayer Subsidiary’s Parkinson’s Treatment Bemdaneprocel Shows Promise in Phase I

Fineline Cube Sep 4, 2023

Germany-based Bayer (ETR: BAYN) has announced that its subsidiary BlueRock Therapeutics’ open-label Phase I study...

Company Drug

AstraZeneca’s Calquence Approved by NMPA for Chronic Lymphocytic Leukemia Treatment

Fineline Cube Sep 4, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received another indication...

Company Drug

Roche’s Alecensa Achieves Milestone in Adjuvant Therapy Trial for Early-Stage NSCLC

Fineline Cube Sep 4, 2023

Switzerland-based pharmaceutical giant Roche (SWX: ROG) has released an update from an interim analysis of...

Company Deals Legal / IP

Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition

Fineline Cube Sep 4, 2023

Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with...

Company Drug

Japan’s MHLW Reviews GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps Indication

Fineline Cube Sep 4, 2023

The Ministry of Health, Labour and Welfare (MHLW) in Japan has begun the review process...

Company Drug

Eli Lilly’s Verzenios Receives NMPA Approval for Extended Indication in Early-Stage Breast Cancer

Fineline Cube Sep 4, 2023

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has announced that the National Medical...

Company Deals

Shanghai Biotech Cataya Secures $35 Million in Series B Financing for Synthetic Biology

Fineline Cube Sep 4, 2023

Shanghai-based biotech company Cataya, which specializes in synthetic biology, has reportedly raised RMB 250 million...

Posts pagination

1 … 432 433 434 … 619

Recent updates

  • Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
  • Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
  • Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial
  • Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa
  • Marubeni Launches Xenleta in China After Complex Licensing Journey
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.